CytRx Corporation Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 American Society of Clinical Oncology Annual Meeting

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin, its lead product candidate, versus doxorubicin in patients with advanced soft tissue sarcomas (STS) has been selected for oral presentation at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30 – June 3 in Chicago.

Help employers find you! Check out all the jobs and post your resume.